Showing results (111-120 of 223) with videos related to

Sort By:
Pageof 23
The Prostate|January 24, 2020
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancerMark C Markowski, Eugene Shenderov, Mario A Eisenberger, et al.
The Prostate|December 22, 2024
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate CancerEtan R Aber, Michael A Carducci, Channing J Paller, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancerChristopher J Strock, Jong-In Park, D Marc Rosen, et al.
Biochemistry|December 22, 2007
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sitesSaurabh Aggarwal, W Nathaniel Brennen, Thomas P Kole, et al.
Molecular Cancer Therapeutics|May 7, 2009
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cellsDonald J Vander Griend, Lizamma Antony, Susan L Dalrymple, et al.
Clinical Genitourinary Cancer|September 20, 2021
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen TherapyMark C Markowski, Sushant Kachhap, Angelo M De Marzo, et al.
Immunotherapy|November 5, 2020
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapyW Nathaniel Brennen, Daniel L J Thorek, Wen Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cellsA T Weeraratna, S L Dalrymple, J C Lamb, et al.
The Prostate|March 8, 2012
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancerJohn T Isaacs, Jason M D'Antonio, Shuangling Chen, et al.
Molecular Cancer Therapeutics|November 16, 2004
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancerSamuel Janssen, Carsten M Jakobsen, D Marc Rosen, et al.
Pageof 23